Seeking Alpha

Edwards Lifesciences (EW +5.4%) shares surge to the top of the S&P after a study shows...

Edwards Lifesciences (EW +5.4%) shares surge to the top of the S&P after a study shows elderly patients receiving its Sapien heart valve implanted through the ribs as part of an expanded access program reaped more benefit than those observed in initial trials. Cannacord, which rates shares a Buy, thinks the data will ease FDA concerns, and raises its target price to $95 from $90.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector